Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Rothman KJ, Arellano F. Elevating the level of scientific discourse. Int J Occup Environ Health. 2005 Sep 1;11(3):327-8.